Nitroglycerin sublingual - Pfizer

Drug Profile

Nitroglycerin sublingual - Pfizer

Alternative Names: Nitrostat

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Parke-Davis Pharmaceutical Division
  • Developer Parke-Davis Pharmaceutical Division; Pfizer
  • Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris

Most Recent Events

  • 29 Nov 2017 Launched for Angina pectoris in Canada (Sublingual) before November 2017
  • 29 Nov 2017 Launched in Angina pectoris in China (Sublingual) before November 2017
  • 29 Nov 2017 Withdrawn for Angina pectoris in Hong Kong (Sublingual) before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top